J 2017

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

SANDECKÁ, Viera, Roman HÁJEK, Luděk POUR, I. SPICKA, V. SCUDLA et. al.

Basic information

Original name

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance

Authors

SANDECKÁ, Viera (703 Slovakia, guarantor), Roman HÁJEK (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic), I. SPICKA (203 Czech Republic), V. SCUDLA (203 Czech Republic), E. GREGORA (203 Czech Republic), J. RADOCHA (203 Czech Republic), L. WALTEROVA (203 Czech Republic), P. KESSLER (203 Czech Republic), L. ZAHRADOVA (203 Czech Republic), D. ADAMOVA (203 Czech Republic), K. VALENTOVA (203 Czech Republic), I. VONKE (203 Czech Republic), J. OBERNAUEROVA (203 Czech Republic), D. STAROSTKA (203 Czech Republic), M. WROBEL (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Aneta MIKULÁŠOVÁ (203 Czech Republic, belonging to the institution), L. RIHOVA (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), J. STRAUB (203 Czech Republic), J. MINARIK (203 Czech Republic), Zdeněk ADAM (203 Czech Republic), Marta KREJČÍ (203 Czech Republic), Zdeněk KRÁL (203 Czech Republic) and V. MAISNAR (203 Czech Republic)

Edition

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2017, 0902-4441

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.595

RIV identification code

RIV/00216224:14110/17:00098729

Organization unit

Faculty of Medicine

UT WoS

000403724300010

Keywords in English

monoclonal gammopathy; multiple myeloma; progression; risk factors

Tags

Tags

International impact, Reviewed
Změněno: 18/3/2018 16:41, Soňa Böhmová

Abstract

V originále

IntroductionMonoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methodsWith the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-basedcohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. ResultsDuring the follow-up period (median 4years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration 1.5g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age 69years, and the level of serum hemoglobin at baseline <12.0g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. ConclusionThe new CMG model was established with an advantage for better identification of MGUS patients at low risk.